NFA
SAGE

Nationwide Fund Advisors’s Sage Therapeutics SAGE Stock Holding History

Nationwide Fund Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,219
Closed -$1.57M – 1702
2017
Q3 		$1.57M Sell
25,219
-447
-2% -$35.1K 0.01% 1554
2017
Q2 		$2.04M Buy
25,666
+1,860
+8% +$134K 0.01% 1420
2017
Q1 		$1.69M Sell
23,806
-6,910
-22% -$405K 0.01% 1483
2016
Q4 		$1.57M Buy
30,716
+66
+0.2% +$3.11K 0.01% 1531
2016
Q3 		$1.41M Buy
30,650
+1,650
+6% +$67.2K 0.01% 1576
2016
Q2 		$874K Buy
29,000
+6,808
+31% +$227K ﹤0.01% 1814
2016
Q1 		$711K Buy
22,192
+1,049
+5% +$36.9K ﹤0.01% 1891
2015
Q4 		$1.23M Buy
21,143
+1,816
+9% +$90K 0.01% 1616
2015
Q3 		$818K Sell
19,327
-1,600
-8% -$98.6K ﹤0.01% 1829
2015
Q2 		$1.53M Sell
20,927
-4,114
-16% -$264K 0.01% 1600
2015
Q1 		$1.26M Buy
25,041
+903
+4% +$38.8K 0.01% 1772
2014
Q4 		$883K Buy
24,138
+18,947
+365% +$706K ﹤0.01% 1873
2014
Q3 		$164K Buy
+5,191
New +$150K ﹤0.01% 2793

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nationwide Fund Advisors's SAGE Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Sage Therapeutics (SAGE) in Q4 2017, closing a stake of 25,219 shares — an estimated $1.57M sold.

Nationwide Fund Advisors first reported a position in SAGE in Q3 2014 and held it in 13 quarters. The position peaked at $2.04M in Q2 2017. 224 funds tracked by Wall St. Rank hold SAGE as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Sage Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 25,219 Sage Therapeutics shares in Q4 2017, an estimated $1.57M.
  • Nationwide Fund Advisors first reported a position in Sage Therapeutics in Q3 2014 and held it in 13 quarters.
  • Nationwide Fund Advisors's Sage Therapeutics position peaked at $2.04M in Q2 2017.
  • 224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.